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Abstract DiC14-amidine is a cationic lipid that was
originally designed as a lipid nanocarrier for nucleic acid
transport, and turned out to be a Toll-like receptor 4
(TLR4) agonist as well. We found that while E. coli
lipopolysaccharide (LPS) is a TLR4 agonist in all species,
diC14-amidine nanoliposomes are full agonists for human,
mouse and cat receptors but weak horse agonists. Taking
advantage of this unusual species specificity, we used
chimeric constructs based on the human and horse se-
quences and identified two regions in the human TLR4 that
modulate the agonist activity of diC14-amidine. Interest-
ingly, these regions lie outside the known LPS-binding
domain. Competition experiments also support our hy-
pothesis that diC14-amidine interacts primarily with TLR4
hydrophobic crevices located at the edges of the TLR4/
TLR4* dimerization interface. We have characterized po-
tential binding modes using molecular docking analysis
and suggest that diC14-amidine nanoliposomes activate
TLR4 by facilitating its dimerization in a process that is
myeloid differentiation 2 (MD-2)-dependent and cluster of
differentiation 14 (CD14)-independent. Our data suggest
that TLR4 may be activated through binding at different
anchoring points, expanding the repertoire of TLR4 ligands
to non-MD-2-binding lipids.
Keywords Toll-like receptor  Cationic lipid 
Nanoparticle  Activation mechanism  Species specificity
Introduction
Toll-like receptor 4 (TLR4) is a member of the innate
immune system’s Pattern Recognition Receptor (PRR)
family, specialized in the recognition of bacterial
lipopolysaccharides (LPS), components of the outer
membrane of Gram-negative bacteria. The interaction be-
tween TLR4 and LPS requires two main co-receptors: the
Myeloid Differentiation Factor 2 (MD-2), a glycoprotein
physically associated with TLR4 on the cell surface and
conferring to TLR4 its responsiveness to LPS and the
Cluster of Differentiation 14 (CD14) which is believed to
transport the LPS into the vicinity of TLR4/MD-2. Upon
agonist recognition, TLR4/MD-2 homodimerizes and ac-
tivates two main signalling pathways that depend on the
adaptors recruited, both triggering the production of pro-
inflammatory cytokines and chemokines: the Myeloid
Differentiation primary response 88 (MyD88)-dependent
cascade leading to the activation of the Nuclear Factor
kappa B (NF-jB) and Activated Protein-1 (AP-1) tran-
scription factors and the TIR-domain-containing adapter-
inducing interferon-b (TRIF)-dependent pathway leading
to the activation of the Interferon Regulatory Factor 3
(IRF-3) [1, 2].
The resolved structure of the dimeric complex TLR4/
MD-2 with bound LPS [3] has revealed that 5 acyl chains
of the hexa-acylated Escherichia coli LPS (abbrv. E. coli
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LPS or EC-LPS) are buried deep inside a hydrophobic
pocket in MD-2, with the 6th acyl chain partially exposed
to the surface of the protein, participating in the dimer-
ization interface. In contrast, lipid IVa, a tetra-acylated
precursor of E. coli LPS, which is an antagonist in human,
is completely buried inside the hydrophobic pocket of MD-
2 in a conformation that prevents TLR4 dimerization [4].
Depending on their structure (i.e. acylation pattern, number
of phosphate groups), but also on the TLR4 and MD-2
mammalian species, LPS from different natural origins or
synthetic LPS derivatives will bind and induce or prevent
signalling with different efficiencies [5–8]. Penta-acylated
lipopolysaccharide from Rhodobacter sphaeroides (RS-
LPS) acts as agonists of TLR4 in horses and hamsters, but
as an antagonist in humans and mice [9–13]; lipid IVa,
mentioned earlier, acts as an antagonist in human, but as an
agonist in mouse, hamster, horse and cow [5, 9, 14–17].
Therefore, swapping experiments in which TLR4 from one
species is used in combination with MD-2 from another
species and inter-species chimera where amino acids found
in one species are mutated with the corresponding residues
from another species have allowed to identify regions in
both TLR4 and MD-2 involved in species dependency of
TLR4 ligands [14, 16, 18–20]. Recently, the comparison of
the crystal structures of mouse TLR4/MD-2/lipid IVa
(agonist) [17] and human MD-2/lipid IVa (antagonist) [4]
confirmed the data obtained using species dependency and
revealed that specific residues present in both mTLR4 and
mMD-2 modulate the charge distribution of the complex,
favouring the agonist positioning of lipid IVa in mouse
TLR4 which promotes dimerization of mTLR4/MD-2/lipid
IVa [17].
We showed previously that a cationic lipid synthesized
in our laboratory, diC14-amidine [21, 22] (Fig. S1), acti-
vates TLR4 and MD-2-dependent MyD88 and TRIF-
dependent signalling pathways in human and murine den-
dritic cells [23–26]. DiC14-amidine’s structure differs
noticeably from the LPS structure (Fig. S1) both in size and
charge, and aggregates into liposomes. We therefore hy-
pothesized that the interaction mode of diC14-amidine
nanoliposomes with TLR4/MD-2 would be different from
traditional ligands such as LPS.
Materials and methods
Constructs
pcDNA3-hTLR4, pcDNA3-eTLR4, pcDNA3-hCD14,
pEFIRES-hMD-2 and pEFIRES-eMD-2 were constructed
as described earlier [16]. TLR4 chimeras were constructed
by overlap extension PCR and point mutations were in-
troduced by site-directed mutagenesis (QuickChange;
Stratagene) and mutations were confirmed by sequencing
as described [16]. The ten different chimeras we used in
this work are represented in Fig. S3: the first group cor-
responds to human TLR4 (H) in which a specific region has
been replaced by its corresponding equine insert (E) to
generate HE chimeras; the second group possesses the
equine backbone (E) which is locally replaced by human
regions (EH chimeras). Constructs that failed to signal to
LPS were excluded from this study.
Materials
DiC14-amidine was synthesized as described earlier [21]
and stored as powder at -20 C. Lipid films were formed
by dissolving powder in chloroform, followed by solvent
evaporation under nitrogen stream, vacuum drying over-
night, and storage at -20 C. Before each experiment,
lipid films were freshly resuspended in filtered Hepes
10 mM heated at 55 C as previously described [22].
EC-LPS (UltraPure LPS—Escherichia coli O111:B4
subtype) and RS-LPS (Rhodobacter sphaeroides LPS)
were obtained from InvivoGen and were freshly prepared
for each experiment in water at a concentration of 1 mg/ml
by vortexing, followed by sonication for 1 min. LPS at
100 ng/ml corresponds approximately to 5–15 nM.
All cell culture media and components were purchased
at Lonza.
Cell culture and transient transfection
Human embryonic kidney cells (HEK 293) were obtained
from ATCC (Manassas, VA, USA). Cells were maintained
in DMEM supplemented with 10 % FCS, 2 mM L-glu-
tamine, 100 U/ml penicillin and 100 lg/ml streptomycin.
HEK293 cells were transfected as previously described
[16]. Briefly, cells were seeded at 7.5 9 104 cells/well in a
96-well plate and transiently transfected 3 days later. Ex-
pression vectors containing cDNA encoding TLR4 (5 ng/
well), MD-2 (1 ng/well), and CD14 (1 ng/well), a NF-jB
transcription reporter vector encoding Firefly luciferase
(10 ng/well pNF-jB-luc; Clontech) and a constitutively
active reporter vector encoding Renilla luciferase (5 ng/
well phRG-TK; Promega) together with empty vector en-
sure that an optimal amount of DNA was mixed with
jetPEI (Polyplus transfection) according to the manufac-
turer’s instructions.
After 48 h cells were stimulated for 6 h with diC14-
amidine (in serum-free DMEM), UltraPure LPS in com-
plete medium, or NiCl2 (Sigma Aldrich) in complete
medium. Cells were then washed with PBS and lysed with
Passive Lysis Buffer (Promega). Luciferase and Renilla
activity were then quantified on a FLUOstar Omega (BMG
Labtech) using home-made luciferase reagent [20 mM
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Tricine, 2.67 mM MgSO4.7H2O, 0.265 mM (MgCO3)4-
Mg(OH)2.5H2O, 0.1 mM EDTA, 33.3 mM DTT, 530 lM
ATP, 270 lM Acetyl CoEnzyme A (Lithium salt), 470 lM
Luciferin (Biosynth), pH 7.8, diluted 2 times in water be-
fore use] or coelenterazine (Biosynth) dissolved in ethanol
at 1 mg/ml and diluted 500 times in PBS before use as
described in [16]. Luciferase luminescence intensity was
normalized to renilla luminescence intensity and data were
expressed as fold induction as compared to non-induced
control or as percentage as compared to LPS. Renilla lu-
minescence serves as a control for experiment-inherent
minor variations concerning cell numbers and transfection
efficiencies between individual wells on the used microtiter
plates. All transfected cells were tested for their ability to
respond to EC-LPS in parallel to other ligands to ensure
that the MD-2/TLR4 constructs were functional and to
control any differences in protein expression efficiency.
For competition assays, 48 h after transfection, cells
were incubated with RS-LPS for 1 h, then cells were
washed and stimulated as described. We used cells pre-
treated with RS-LPS before diC14-amidine stimulation or
EC-LPS stimulation rather than co-administration, to pre-
vent direct contact between lipids of opposing charges
which could lead to possible interference within their re-
spective micellar structures rather than at the level of
receptor binding.
The THP1 cells were obtained from ATCC (Manassas,
VA, USA) and were maintained in RPMI medium with
25 mM HEPES supplemented with 10 % FBS, 2 mM L-
glutamine, 100 U/ml penicillin and 100 lg/ml strepto-
mycin, 1 mM sodium pyruvate and 20 lM
2-Mercaptoethanol, at 37 C at 5 % CO2.
For experiments, cells were primed with 10 nM phorbol
12-myristate 13-acetate (PMA—Sigma Aldrich) to induce
differentiation 28 h before stimulation. After this incuba-
tion period, the PMA-containing medium was removed and
replaced with PMA-free complete medium for 4 h at 37 C
at 5 % CO2. Cells were then preincubated with the indi-
cated amounts of neutralizing antibodies against human
CD14 (InvivoGen) or Control antibody (InvivoGen) at a
final concentration of 20 lg/mL for 1 h, then stimulated
with the indicated amounts of EC-LPS or diC14-amidine in
serum-free medium (added in concentrated form into the
antibody-containing medium to reach their final stimulant
concentrations). After 4 h incubation, the supernatants
were recovered and analysed by ELISA following
manufacturer’s instructions (DuoSet kits from R&D
Systems).
Statistical analysis
Multiple comparisons versus control group for each treat-
ment within groups were made using One-Way ANOVA
(Holm–Sidak method) or Kruskal–Wallis One-Way Ana-
lysis of Variance on Ranks (Dunnett’s method) when
normality test failed, using SigmaPlot software.
Computational methods
DiC14-amidine model
The molecular structure of diC14-amidine was generated
ab initio in Sybyl software version 8.1.1 (Tripos). The ge-
ometry of the lipid was optimized using the Powell
minimisation method, with initial optimization based on the
Simplex method, and with a gradient of 0.05 kcal/mol and a
maximum of 100 cycles of iteration. Partial charges were
computed based on the Gasteiger–Hu¨ckel charge method.
TLR4 and MD-2 templates
The molecular structures of the extracellular region of
human TLR4 on its own and bound to MD-2 proteins as
observed in the crystal structure of the LPS complex [3]
were used for surface visualization and molecular docking
of diC14-amidine molecules. Docking experiments were
performed upon removal of the E. coli LPS ligands from
the coordinate file.
Molecular docking
Autodock Vina software package [27] was used for docking
diC14-amidine on TLR4-MD-2. The TLR4:MD-2 dimeric
receptor complex was treated as a rigid protein complex.
DiC14-amidine was fully flexible as its 30 torsion angles are
within themaximumallowed limit. TheAutogrid parameters
were computed for the entire TLR4-MD-2 complex, with a
grid sized 100 9 100 9 100 A˚3, but also for smaller areas
centred on the regions shown to be important by mutage-
nesis, with a grid size of 40 9 40 9 40 A˚3. The grid was
centred on the complex at x = ? 12.322; y = -7.964;
z = -5.891. The default optimization parameters for the
iterated local search global optimizer of Vina were used
except for exhaustiveness, which was increased propor-
tionally to the size of the grid (the default value of 8 was
increased up to 32). Docking poses of the ligand were anal-
ysed and structural images were generated in PyMol (http://
www.pymol.org), Chimera [28], and LigPlot [29].
Results
CD14 is not required in diC14-amidine activity
To decipher the TLR4 activation mechanism induced by
diC14-amidine, we wanted in a first step to determine the
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role of the co-receptors MD-2 and CD14 in the agonist
activity of diC14-amidine. The importance of TLR4 and
MD-2 was already demonstrated by the inability of
TLR4-/- and MD-2-/- bone marrow-derived dendritic
cells to secrete IL-12p40 in response to diC14-amidine
stimulation; however, the role of CD14 was not fully ad-
dressed so far [23]. We therefore transfected HEK293 cells
with the plasmids coding for each protein in different
combinations (Fig. 1a) and the cells were then stimulated
with diC14-amidine liposomes or EC-LPS in the absence
of serum.
As expected, in the absence of TLR4, MD-2 and CD14
no activation was observed for both ligands. Further, nei-
ther EC-LPS nor diC14-amidine was able to activate NF-
jB in the absence of MD-2 even in the presence of TLR4
and CD14 (Fig. 1a, right). However, while EC-LPS is
unable to activate TLR4/MD-2 in the absence of CD14,
diC14-amidine’s TLR4 agonist activity was not affected by
the lack of CD14, and was even found to have slightly
increased.
We then evaluated CD14 requirement for NF-jB but
also for IRF-3 induction on THP1 cells (by quantifying
TNF-a and IP-10 in supernatants) by inhibiting CD14 us-
ing blocking antibodies (Fig. S2). This clearly confirms the
non-requirement of CD14 for NF-jB activation by diC14-
amidine, but more surprisingly, stimulation of the cells
with diC14-amidine also resulted in the secretion of hIP10
when CD14 was neutralized, demonstrating that the ca-
tionic lipid also does not require CD14 to trigger the TRIF-
dependent pathway.
Fig. 1 Human TLR4 drives the activity of diC14-amidine. HEK 293
cells were transfected with plasmids encoding human TLR4 and/or
MD-2 and/or CD14 (a) or TLR4 and MD2 from different species (b,
c) with (b) or without (c) human CD14 together with firefly luciferase
reporter plasmid dependent of NF-jB activation. Two days after
transfection, cells were stimulated for 6 h with diC14-amidine or
LPS. Luciferase was then quantified in cell lysates. Data are
represented as fold induction as compared to non-stimulated control
for each condition. Means are expressed ± standard deviation with
n = 3. Representative of at least 2 independent experiments.
*p\ 0.05, **p\ 0.01 as compared to control (ANOVA). a Activa-
tion of NF-jB by diC14-amidine requires both TLR4 and MD-2 but
not CD14. b Species-dependent activity of diC14-amidine. H human,
C cat, E equine. c Partial activation of NF-jB by diC14-amidine is
maintained in the presence of human TLR4
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Species-specific activity of diC14-amidine
We previously showed that diC14-amidine is a TLR4
agonist in both human and mouse dendritic cells [23]. To
understand the way diC14-amidine interacts with TLR4/
MD-2, we compared the TLR4 agonist activity of diC14-
amidine in two further species (cat and horse) by trans-
fecting HEK293 cells with plasmids coding for TLR4,
MD2 and CD14 from human (H), cat (C) and horse (E).
We demonstrated (Fig. 1b) that, while EC-LPS is an ago-
nist in all species, diC14-amidine is a full agonist for
human and cat receptors, but induced low levels of acti-
vation in horse. Since we were unable to detect an
antagonist effect of diC14-amidine on the full agonist EC-
LPS (data not shown), we therefore consider this com-
pound to be a weak agonist in horse TLR4. This suggests
that diC14-amidine is unable to induce signal transduction
in the horse, while it binds and activates TLR4/MD-2 in
other species.
Horse MD-2 does not fully abolish diC14-amidine
signalling activity, in contrast to horse TLR4,
in inter-species assays
To determine whether MD-2 or TLR4, or both, confer the
observed species-specific differences in signalling, we
conducted a series of MD-2/TLR4 swapping experiments
(Fig. 1c). Cat TLR4/MD2, like human TLR4/MD2, was
efficiently activated by diC14-amidine and comparative
analysis between cat and human TLR4/MD2 was not likely
to provide further information on how diC14-amidine in-
teracts with this receptor complex. We focused therefore on
human and horse comparisons. Whilst human TLR4 and
MD-2 are fully activated by diC14-amidine nanolipo-
somes, and the equine TLR4 complex (eTLR4 ? eMD-2)
or the complex eTLR4 ? hMD-2 are not, we still observed
a partial activation of NF-jB occurring by stimulating with
diC14-amidine the combination of hTLR4 and eMD2
(Fig. 1c). In contrast, EC-LPS was able to fully activate all
combinations of human and horse TLR4 and MD-2 (see
Fig. S3).
The importance of TLR4 over MD-2 suggests a different
mode of TLR4 activation by diC14-amidine as compared
to the more classical LPS derivatives. By comparison,
similar experiments made with lipid IVa (agonist in horse
and mouse but antagonist in human) showed that this li-
gand required both horse TLR4 and horse MD-2 or both
mouse TLR4 and MD-2 to be active [16, 19] (no activation
was found with combination of hTLR4/eMD-2 or eTLR4/
hMD-2) which was further confirmed by the crystal
structures of mouse TLR4/MD-2/lipid IVa and human MD-
2/lipid IVa [4, 17]. Interestingly, another human TLR4
activator has been reported to mediate TLR4 signalling
irrespectively of the origin of the transfected MD-2 co-
receptor: nickel ions [30]. Schmidt and colleagues [30]
proposed that nickel ions activate NF-jB through binding
of species-specific histidine residues in TLR4, triggering
the formation of a TLR4/MD-2:TLR4*/MD-2* dimer that
structurally resembles the one induced by LPS [30].
Although MD-2 is required for TLR4 dimerization, it does
not participate in nickel binding explaining why species
dependency of the agonist activity of nickel ions is solely
dependent on human TLR4 [31].
Antagonism of diC14-amidine activation of TLR4
To determine whether the recognition interface of diC14-
amidine is different from the known LPS-binding site, we
compared the effect of a TLR4 antagonist, Rhodobacter
sphaeroides LPS (RS-LPS), on the TLR4 agonist activity
of diC14-amidine and E. coli LPS (Fig. 2). RS-LPS (Fig.
S1) is a potent antagonist for human TLR4, interacting
with TLR4/MD-2 by inserting its lipid tails into MD-2’s
binding pocket [13].
Figure 2 shows the dose–response curves for EC-LPS
(B) and diC14-amidine (A) upon pretreatment with in-
creasing concentrations of RS-LPS. As expected, RS-LPS
and EC-LPS compete for the same binding site, so the
potency of the response to LPS was reduced after pre-
treatment with RS-LPS, but with no alteration of the
maximal response reached at high concentrations of EC-
LPS (i.e. showing a parallel rightward shift of agonist
dose–response curves). In contrast, RS-LPS decreases the
potency and magnitude of the maximum response of
diC14-amidine (RS-LPS effect cannot be negated, no
matter how much diC14-amidine is present). This non-
competitive antagonism of RS-LPS on diC14-amidine’s
activity in contrast to the competitive antagonism seen for
EC-LPS suggests that diC14-amidine binds at a different
site on the TLR4/MD-2 complex. The same behaviour was
found for nickel ions (Fig. 2c), underlining the similarities
between these two TLR4 activators.
To identify the regions of TLR4 involved in the diC14-
amidine agonist activity, we tested the ability of human/
horse chimeras, in which regions of TLR4 from one species
are exchanged with the corresponding ones from the other
species, to be activated by diC14-amidine (Fig. 3a, b). This
approach was previously used to identify residues in TLR4
and MD-2 that are important for the recognition of lipid
IVa [14, 16, 19, 20] or RS-LPS [13] as TLR4 agonists and
which were further confirmed by the crystal structures of
human TLR4/MD2/EC-LPS, mouse TLR4/MD-2/lipid IVa
and human MD-2/lipid IVa [3, 4, 17]. We constructed
several chimeras first based on the regions known to be
important in the case of lipid IVa or RS-LPS. Indeed, for
these ligands, the LRR 14–18 region is critical for their
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Fig. 2 Antagonist effect of RS-LPS on diC14-amidine, LPS and
nickel TLR4 agonist activities. HEK 293 cells were transfected with
plasmids encoding human CD14, MD-2, and TLR4, together with
reporter plasmids. Two days after transfection, cells were pretreated
with the indicated amount of RS-LPS for 1 h, and then washed twice.
Cells were then stimulated with diC14-amidine (a), LPS (b) or NiCl2
(c), for 6 h, and luciferase was quantified in cell lysates. Means are
expressed ± standard deviation with n = 3. Representative of at least
2 independent experiments
Fig. 3 TLR4 leucine-rich repeats LRR 9–13 and 18–20 are important
for the activity of diC14-amidine. a, b, c HEK 293 cells were
transfected with plasmids encoding human CD14, MD-2, and
chimeric/mutant TLR4, together with reporter plasmids, then
stimulated 48 h later with diC14-amidine for 6 h before quantification
of NF-jB activation. Luciferase was then quantified in cell lysates.
Data are represented as fold induction as compared to non-stimulated
condition (control) for each species. Means are expressed ± standard
deviation with n = 3–15. Representative of at least 2 independent
experiments. *p\ 0.05, **p\ 0.01 as compared to control
(ANOVA). d Localisation of the important residues for diC14-
amidine’s agonist activity based on the known structure of TLR4/
MD-2/LPS [3]
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agonist activity in horse TLR4 and corresponds to the
dimerization interface in the C-terminal domain interacting
with one lipid chain of LPS [3]. A second region was also
explored, corresponding to the primary binding interface
(i.e. before ligand binding) between TLR4 and MD-2 lo-
cated in the concave surface (LRR 9–13) of TLR4 [3]
which is also known to interact with LPS derivative
headgroups.
The chimeras HE (LRR 14–18) (human TLR4 with the
equine LRR 14–18 insert), EH (LRR18-TM) (equine TLR4
with the human LRR 18-TM insert) and EH (14–20)
(equine TLR4 with the human LRR 14–20 insert) are ac-
tivated by diC14-amidine (Fig. 3a). Since these chimeras
have only the human region LRR 18–20 in common (Fig.
S4), this result suggests that residues 484–535 are critical
for diC14-amidine recognition as an agonist. Another set of
chimeras were also activated by diC14-amidine: HE (LRR
14–18) (already mentioned here above), EH (LRR9-TM)
(equine TLR4 with the human LRR 9-TM insert) and EH
(LRR9-13) (equine TLR4 with the human LRR 9–13 in-
sert) (Fig. 3b), suggesting that a second region,
corresponding to LRR 9–13 (see Fig. S4) (i.e. residues
252–370) is also involved in TLR4 agonist activity of
diC14-amidine.
Species-specific point mutagenesis identifies in TLR4
critical residues for the recognition of diC14-
amidine
The comparison of the human and equine sequences in the
LRR 9–13 and 18–20 regions (Fig. S5) reveals that only 20
amino acids are different between horse and human in the
LRR 18–20 region and 44 residues in the LRR 9–13 region.
To identify the residues in human TLR4 important for
diC14-amidine interaction, we produced several point mu-
tations of human TLR4 whereby one or two residues were
replaced by their equine homologues: R264K, GN267-8RK,
N268K, G343E, Q484K, QE484-5KD, QCQ505-7KCN,
PT513-4QE and FF532-3LL using site-directed mutage-
nesis, and tested their activity in response to diC14-amidine
(Fig. 3c). Most mutants responded similarly to wild-type
human TLR4 to diC14-amidine, while mutants FF532-
533LL and PT513-514QE showed a decreased activity in
response to diC14-amidine and mutants G343E and
QCQ505-7KCN were not activated by diC14-amidine,
similar to equine TLR4. Interestingly, amino acids G343,
Q505, Q507 and F533 do not interact with LPS in the
crystal structure of TLR4/MD-2/LPS [3] but are important
in TLR4-TLR4* interface interaction. The residues corre-
sponding to Q507 and Q344 in horse (N508 and G345) are
unique to this species (Fig. S5) and may therefore explain
the difference of diC14-amidine’s TLR4 agonist activity for
horse as compared to other species.
It is striking that the mutated residues that lead to a loss
(or a decrease) of the TLR4 agonist activity of diC14-
amidine are located in the TLR4-TLR4* dimerization in-
terface (see Fig. 3d), while TLR4 residues involved in the
interaction with the headgroup or the lipid chains of LPS
[3] do not influence diC14-amidine’s agonist activity. This
strongly suggests that diC14-amidine interacts with TLR4
via a mechanism different to that previously proposed for
LPS and its derivatives [3, 17]. Therefore, although the
lipidic nature of diC14-amidine suggested that it was likely
to interact with MD-2 and possess the so-called MD-2-
related lipid-recognition domain [32] to activate the TLR4
pathway, our pharmacological analysis and mutagenesis
data now suggests that this is unlikely.
TLR4 hydrophobic crevices are potential binding
sites for diC14-amidine
TLR4 possesses hydrophobic crevices that are spread all
over its leucine and cysteine-rich regions with volumes up
to 335 A˚3 according to CastP server calculations [33]
(Fig. 4). We postulate, therefore, that diC14-amidine might
be able to bind TLR4 through interaction with its hy-
drophobic crevices, with the possibility of binding several
diC14-amidine molecules to several hydrophobic crevices
throughout the TLR4-TLR4* interface. However, none of
the hydrophobic grooves in TLR4 are as deep as those
found in TLR2 which help to form TLR2-TLR1 and TLR2-
TLR6 heterodimers in the presence of bacterial tri- and di-
acylated lipopeptides (BLPs), respectively [34, 35]. BLPs
are indispensable to hold these ectodomains together via
hydrophilic and hydrophobic interactions. While two ester-
bound acyl chains are inserted into a pocket in TLR2, the
amide-bound lipid of triacylated BLPs is fitted into a hy-
drophobic channel in TLR1. The latter is blocked off by
Phe residues in TLR6 explaining the ligand specificity of
the system [34, 35]. To clarify the mode of action of diC14-
amidine, we generated docking models for this molecule in
complex with the TLR4 ectodomain and the dimeric TLR4/
MD-2 complex [3]. DiC14-amidine could be docked in the
vicinity of LRR19 residues Q505 and Q507 [at -5.2 k-
cal/mol and with an apparent Ki value in the micromolar
range (150 lM)]. This putative binding site is located at the
TLR4-TLR4* interface with the headgroup wedged be-
tween Q505 and Q507 and both myristate chains at the
ascending flanks of TLR4 LRR 16–19 (Fig. 5). The latter
Gln residue is conserved in human, mouse and cat and
replaced by an Asn in horse TLR4. The shorter side chain
in horse might explain the weaker activity of diC14-ami-
dine in horse compared to other mammalian species.
Therefore, our docking model proposes a potential binding
site for diC14-amidine molecules in the proximity of the
hydrophobic crevices found to be important in this study.
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Discussion
Here, we show how the cationic lipid diC14-amidine, a
molecule initially designed for use as a lipid-based
nanocarrier in gene therapy, is immunostimulatory. Our
data suggest that diC14-amidine interacts directly with
TLR4 and induces its dimerization via cross-linking two
receptor chains. The subsequent cell signalling mechanism
is analogous to the one that was proposed for TLR4 acti-
vation by nickel ions [30]. As already mentioned, it was
previously proposed that nickel and cobalt ions trigger
MD-2 dependent TLR4 dimerization and activation
through chelation of species-specific histidine residues
(H431, H456 and H458 on both TLR4 and TLR4*) located
at the dimerization interface of human TLR4-TLR4 [30].
Oblak et al. [31] recently confirmed that nickel-binding site
is completely independent of the endotoxin-binding site but
proposed that MD-2 nevertheless contributes to the inter-
action by providing supporting hydrophobic interactions
with TLR4 which stabilize the TLR4/MD-2/Ni2? complex
in a proper conformation for cellular activation.
Cross-linking of TLR4 ectodomains, resulting in their
activation, may also occur following incubation of cells
with antibodies directed against TLR4 [36, 37]. This im-
plies that different anchoring points can lead to
dimerization and foresees other possible ways of TLR4
activation that have not been explored until now. It is likely
that, in the future, other microbial or endogenous TLR4
stimulators (like amino acid-containing lipid present in
many Gram-negative bacteria [38, 39], but also ganglio-
sides [40] or ceramides [41, 42], which all share common
structural features with diC14-amidine) will be
Fig. 4 Hydrophobic crevices on the surface of TLR4’s ectodomain.
a Molecular surface of the TLR4 ectodomain coloured according to
its hydrophobicity (orange hydrophobic, blue hydrophilic). Species-
specific residues that have been targeted by point mutagenesis are
highlighted in magenta in the left panels. b, c Close-up views
illustrate the residues’ proximity to hydrophobic crevices, potentially
involved in diC14-amidine binding
3978 C. Lonez et al.
123
demonstrated to be able to activate TLR4 through inter-
action with the TLR4 dimerization interface, expanding the
possible ligands of TLR4 to non-MD-2-binding lipids. Fi-
nally, this new recognition interface might also be involved
in the recognition of nanoparticles by the innate immune
system. Indeed, diC14-amidine liposomes are not the only
example of lipid-based nanoparticles, or more generally of
engineered nanoparticles, that activate Toll-like receptor 4
[26, 43–46]. Our work can therefore contribute to a deeper
knowledge of the effects of engineered nanoparticles on the
immune system, a necessary step for their safer use in
nanomedicine and for an improved therapeutic efficacy.
In addition, our data also demonstrate that diC14-ami-
dine does not require CD14 to activate MyD88-dependent
pathways. Similar CD14-independent behaviour has been
reported for two synthetic lipid A derivatives: MPL
(Monophosphoryl Lipid A) and CRX-527 and for the rough
form of LPS (LPS lacking the full-length O-antigen
chains—see Fig. S1) [47–50]. CD14 ligand carrier role has
been established beyond doubt and is involved in the pre-
sentation of LPS to TLR4/MD-2 for initiating the MyD88-
dependent pathway [51]. The lack of the long polysac-
charide chains in these LPS derivatives probably allows
their better incorporation into and higher mobility in the
mammalian cell membrane, providing a better access to
protein receptors [48]. Therefore, the ability of diC14-
amidine, with its small hydrophilic headgroup, to be in-
serted into cell membranes after fusion [52, 53] offers a
straightforward explanation for why this ligand does not
require CD14 for inducing the MyD88-dependent pathway.
Finally, while it was generally accepted that CD14 was
required for the LPS-induced endocytosis of TLR4 [54]
which is considered necessary to enable the activation of
the TRIF-dependent pathway [51, 55], our results demon-
strate that CD14 is also not required to trigger the TRIF-
dependent pathway induced by diC14-amidine, in contrast
Fig. 5 Potential docking of diC14-amidine within the TLR4 dimer
interface. Docking pause at -5.2 kcal/mol involving hydrogen bonds
with the side chain of Gln 507 and the main chain carbonyl groups of
Gly 480, Asn 481, and Gln 505, as well as a number of hydrophobic
contacts at the TLR4 dimer interface. Figure generated by LigPlot
[29]
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to stimulation by rough LPS, MPL and CRX-527 [47–50].
Such behaviour has been described for LPS-coated latex
beads [54] or LPS-formulated liposomes [56], which
showed enhanced LPS endocytosis in the absence of CD14
(as compared to free LPS) thus confirming the importance
of endocytosis for the TRIF-dependent signalling pathway
[54, 55]. However, those LPS formulations were found
unable to activate the My88-dependent signalling pathway
from inside the endosomes [56]. The uniqueness of diC14-
amidine, as compared to other known TLR4 ligands, to
activate both signalling pathways in the absence of CD14,
may therefore be related to the fact that diC14-amidine
liposomes enter the cells via both endocytosis and fusion
processes [53, 57].
In conclusion, here we show that the TLR4 agonist ac-
tivity of the cationic lipid nanocarrier diC14-amidine is
primarily dependent on its interaction with TLR4 by a
mechanism likely similar to that proposed for nickel and
cobalt ions. Important residues located at the N- and
C-terminal edges of the TLR4/TLR4* dimerization inter-
face are distinct from those reported for LPS binding and
explain why two molecules as structurally different as
diC14-amidine and LPS are both TLR4 activators. This
may represent a new lead in developing compounds tar-
geting these interactions in TLR4 without affecting the
other functionalities of the receptor, in particular the
recognition of conventional ligands.
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